Abbvie-Header Abbvie-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IRL201104

            Therapeutic Area: Gastroenterology Product Name: ‘1104

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Revolo Biotherapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 15, 2021


            CordenPharma will Provide manufacturing support for Revolo Bio’s first-in-class peptide and immune system resetting drug product, ‘1104, for its upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease.